Global Point-of-Care CRISPR Diagnostic Kit Market Strategic Research Report

The global point-of-care (POC) CRISPR diagnostic kit market stands at an estimated USD 1.38 billion in 2024, having emerged from near-nascent commercial status less than a decade ago to occupy a strategically critical position within the broader molecular diagnostics landscape. CRISPR-based diagnostics—distinguished by their ability to identify specific nucleic acid sequences with high sensitivity and specificity without the thermal cycling infrastructure demanded by PCR—are rapidly transitioning from research-grade tools to field-deployable clinical assets. This shift is reshaping pandemic preparedness frameworks, enabling decentralized infectious disease surveillance, and attracting sustained capital investment from governments, multilateral health agencies, and private biopharma innovators across both mature and emerging economies. The COVID-19 pandemic served as an accelerant, validating rapid molecular detection platforms and embedding POC CRISPR diagnostics into procurement pipelines that previously favored strip-based antigen testing or centralized PCR workflows.

Three distinct forces are propelling market expansion through the forecast period. First, the accelerating burden of antimicrobial-resistant infections is generating urgent demand for rapid, accurate pathogen identification at the bedside and in primary care settings, where empirical antibiotic prescribing currently predominates. CRISPR-based kits offer a potential resolution to this diagnostic gap by delivering results in 30 to 60 minutes without laboratory infrastructure. Second, regulatory pathways are becoming progressively more accommodating: the U.S. FDA's Emergency Use Authorization mechanism—first activated at scale for SARS-CoV-2—has created a precedent that innovators are now applying to sexually transmitted infection (STI) panels, neglected tropical disease assays, and oncology liquid biopsy applications, compressing time-to-market materially. Third, sustained public-sector procurement commitments—including BARDA contracts in the United States, the European Health Emergency Preparedness and Response Authority mandates, and CEPI-funded development programs—are de-risking commercial scale-up. The principal restraint remains assay multiplexing complexity: engineering CRISPR guide RNAs to discriminate reliably among closely related pathogen variants in low-resource settings, while maintaining regulatory-grade reproducibility, continues to challenge developers and constrains addressable indications.

This report delivers a comprehensive, data-anchored analysis of the POC CRISPR diagnostic kit market across the 2025–2032 forecast horizon, with historical context extending to 2019. Coverage encompasses segmentation by kit type, detection technology, and end-use application, alongside regional and country-level granularity across six geographies. Corporate strategy teams evaluating pipeline acquisitions, investment analysts assessing venture and growth-equity opportunities, M&A advisors mapping consolidation trajectories, and procurement managers benchmarking supplier capabilities will find this report an indispensable decision-support resource.